Tag: FDA


William Horwitz

Whistleblower Lawsuit Against Drug Maker Fails Because “Off-Guideline” Marketing Does Not Constitute “Off-Label” Marketing

Posted on November 27th, by William Horwitz in Labor & Employment, Litigation. No Comments

In welcome news for the pharmaceutical industry, the U.S. District Court for the Eastern District of New York, in United States ex rel. Polansky v. Pfizer, Inc., 2012 U.S. Dist. LEXIS 163557 (E.D.N.Y. Nov. 15, 2012), issued a decision distinguishing between unlawful “off-label” marketing and lawfully marketing a drug for use outside of recommended guidelines. By way of background, the Food and Drug Administration approves “labels” (which, in some cases, may be lengthy and more akin to pamphlets or brochures) that must accompany prescription medications.  A label states the purposes for which a medication has been determined to be safe and effective, and pharmaceutical companies are prohibited from promoting or marketing the medication for other “off-label” uses.

Since early 2004, Pfizer, Inc. has been defending a qui tam action that its former Director of Outcomes Management Strategies, Dr. Jesse Polansky, filed under … Read More »




From the Blog

FDA Final Guidance on Mobile Medical Applications

Summary

On September 23, 2013, the FDA issued a guidance (“Final Guidance”) explaining how medical device regulations will be applied to medical mobile applications (MMAs)....

Impact of Healthcare Mobile Apps on Treatment

The use of healthcare applications on mobile devices continues to have a growing impact on medical treatment as consumers are using mobile devices to...

Photocopiers – A Recurring Data Security Risk

In a case that illustrates the data privacy risks associated with modern copiers, the United States Department of Health and Human Resources (HHS) has...